White Papers

1. Gene Therapy For Parkinson’s Disease: Strategies And Operational Requirements 7/29/2021

   Gene therapy holds great promise as a potential treatment for Parkinson’s disease, a disorder for which currently available medications do not causally treat the underlying disease mechanisms. Download the available white paper to find out more.

2. The Importance Of Decentralized Clinical Trials 7/27/2021

   While the standards and value of clinical trials remain high, new implementation techniques have allowed for the adoption of decentralized clinical trials. Download the available white paper to find out more.

3. Cracking The Code On Clinical Trial Recruitment 7/27/2021

   Despite the amount of money and effort sponsors and other research stakeholders invest into recruitment, 80% of studies fail to enroll enough patients on time, resulting in costly timeline extensions and site additions. Download the available white paper to find out more about this dilemma.

4. The Emerging Pharmaco’s Dilemma: Make A Deal…Or Not? 7/26/2021

   IQVIA™ Biotech analyzed the approaches of companies that launched products for the first time between 2006 and 2015 to understand their funding/commercialization strategies. This white paper presents the results of this analysis and discuss the implications for the three types of players involved.

5. Partnering Solutions For Emerging Biopharma 7/26/2021

   This paper is the first part of a series of articles aimed at helping the EBP executive and his/her team members better assess the value of a “partnered” outsourcing approach across the continuum of development and commercialization, and potential approaches to mapping out the right fit for their organizational needs.

6. The Nuances Of Hematologic Oncology Clinical Trials 7/26/2021

   This paper examines the requirements for effectively and successfully conducting hematologic oncology clinical trials.

7. Natural History Studies For Rare Diseases: Development Strategies For External Comparator Arms Leveraging Real World Insights 7/26/2021

   This paper explores essential principles for defining the right strategy for natural history studies and how to design such studies in a way that the data can be used as an external comparator to augment future regulatory filings and payer submissions.

8. How Sponsors Can Achieve Operational Efficiency With RTSM 7/16/2021

   Randomization & Trial Supply Management (RTSM) aims to alleviate these pain points by solving high-risk and high-cost trial needs through an intelligent approach to operational management. Due to the inherently changing nature of randomized trials, both adaptive designs and master protocols require a highly sophisticated RTSM solution to swiftly and efficiently introduce mid-study protocol adjustments. In this whitepaper, read about the benefits of incorporating a robust RTSM.

9. Patient Engagement Guide For Sponsors And CROs 7/16/2021

   Now, more than ever, sponsors and CROs need to prioritize including patient engagement in their study builds from the ground-up. But effective, sustainable patient engagement goes beyond single-focused solutions for recruitment and retention. Read below to see how sponsors and CROs must put themselves into the mindsets of their patients and find ways to incorporate their needs into the entire clinical trial lifecycle.

10. Overcoming Pediatric Trial Challenges 7/15/2021

    As the number of pediatric trials being conducted increases, there are several challenges confronting parents, guardians, patients and pharmaceutical companies. One of the biggest of these issues is that it is difficult to enroll participants in pediatric trials. However, these five strategies can help make it easier to enroll trial participants and complete successful trials.